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98Objective: Operation for infective endocarditis is associated with the highest mortality of any valve disease,
with overall rates of in-hospital mortality exceeding 20%. The Society of Thoracic Surgeons Adult Cardiac Sur-
gery Databasewas examined to develop a simple risk scoring system and identify areas for quality improvement.
Methods: From 2002 through 2008, 19,543 operations were performed for infective endocarditis. Logistic
regression analysis related baseline characteristics to both operative mortality and a composite of mortality
and major morbidity within 30 days. Points were assigned to each risk factor, and estimated risk was obtained
by averaging events for all patients having the same number of points.
Results: Overall unadjusted mortality was 8.2%, and complications occurred in 53%. Significant preoperative
risk factors for mortality (associated points) were as follows: emergency, salvage status, or cardiogenic shock
(17), preoperative hemodialysis, renal failure, or creatinine level less than 2.0 (12), preoperative inotropic or
balloon pump support (10), active (vs treated) endocarditis (10), multiple valve involvement (9), insulin-
dependent diabetes (8), arrhythmia (8), previous cardiac surgery (7), urgent status without cardiogenic shock
(6), non–insulin-dependent diabetes (6), hypertension (5), and chronic lung disease (5), with a C statistic of
0.7578 (all P<.001). Risk-adjusted mortality and major morbidity were unchanged over the course of the study.
In the entire data set, mortality was better if ‘‘any valve’’ was repaired (odds ratio ¼ 0.76; P ¼ .0023).
Conclusions: Operative mortality for surgically treated infective endocarditis is substantially lower than
reported in-hospital mortality rates for infective endocarditis. The described risk scoring system will inform
clinical decision-making in these complex patients. (J Thorac Cardiovasc Surg 2011;141:98-106)Supplemental material is available online.Despite advances in medical and surgical therapy, the inci-
dence of infective endocarditis (IE) has not decreased over
the past 30 years.1 In the United States, IE affects approxi-
mately 15,000 patients each year with an in-hospital mortal-
ity exceeding 20%.2,3 Proper decisions regarding the
indications, timing, and performance of cardiac surgery in
patients with IE have the potential to further reduce the
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The Journal of Thoracic and Cardiovascular SurgeIncreases in several risk factors, including an expansion
of the elderly population with degenerative valve disease
and a rise in staphylococcal infections, suggest that IE
will remain a significant health problem in the future.4 Sur-
gical therapy remains an invaluable intervention in the treat-
ment of IE, yet it also carries the highest mortality of any
surgical intervention for heart valve disease.5-7 An
opportunity may exist to improve the care of patients with
IE by optimizing the timing and application of surgical
therapy.8
Little is known about the surgical risk factors and optimal
patient selection in patients with IE.9 The clinical scenarios
encountered by surgeons, patients, and their families are of-
ten very complex and require rapid decision-making involv-
ing high-risk surgery without adequate data. Given the
relatively small number of cases of IE at an individual insti-
tution, obtaining large numbers of patients for study can be
difficult. The Society of Thoracic Surgeons Adult Cardiac
Surgery Database (STS ACSD) provides an excellent op-
portunity to study large numbers of patients undergoing sur-
gery for IE. Surgical outcomes of selected groups of
patients with IE in the STS ACSD, such as mitral valve sub-
groups or those with dialysis-dependent renal failure, have
been studied previously, but the characteristics of the entire
cohort of patients with IE have not been defined.6ry c January 2011
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Gaca et al Acquired Cardiovascular DiseaseTherefore, the purpose of this study was to examine the STS
ACSD to (1) identify risk factors that influence operative
morbidity and mortality in surgery for IE and (2) use these
risk factors to develop a simple bedside scoring system for
clinical decision-making.A
C
DMETHODS
Data Set
The STS ACSDwas established in 1989 and includes data from nearly 3
million cardiac surgical operations from over 90% of cardiac surgical cen-
ters in North America.10 Patient variables are entered using uniform defi-
nitions and a dedicated software system, and data storage and analysis
are performed at the Duke Clinical Research Institute. The population
for this study consisted of all patients with the diagnosis of IE who under-
went surgery on the aortic, mitral, and/or tricuspid valves at STS participat-
ing hospitals between 2002 and 2008. This era was selected because it
represented a large patient population with the most complete data avail-
able in the STS ACSD. Data were collected using the forms provided at
http://www.sts.org/doc/8428. The total number of valvular surgical
procedures in the STS ACSD during the study period was 416,227. Of
these, 19,730 (4.7%) valvular procedures were performed for IE, and
this group forms the study population. Sites were excluded if data were
missing on age (0.05%), gender (0.04%), status of surgery (0.11%),
cardiogenic shock (0.13%), and endocarditis type (0.70%). Sites also
were excluded if more than 20% of patients had no complication
information reported (0.17%). If any of the sites failed to meet these
criteria on data reporting, the entirety of their data was excluded.
Preoperative characteristics and postoperative complications were en-
tered in the data set as defined in the STS data forms. Formal STS defini-
tions include the following: If the patient is currently being treated for
endocarditis, the disease is considered active. If no antibiotic medication
(other than prophylactic medication) is being given at the time of surgery,
then the infection is considered treated. Operative status is considered elec-
tive if the patient’s cardiac function has been stable in the days or weeks
before the operation and the procedure could be deferred without increased
risk of compromised cardiac outcome. Urgent status means that the proce-
dure is required during the same hospitalization to minimize chance of fur-
ther clinical deterioration. Emergency status means the patient requiring
emergency operations will have ongoing, refractory (difficult, complicated,
and/or unmanageable) unrelenting cardiac compromise, with or without
hemodynamic instability, and not responsive to any form of therapy except
cardiac surgery. An emergency operation is one in which there should be no
delay in providing operative intervention. Additional STS definitions of the
preoperative variables and postoperative complications are available at
http://209.220.160.181/STSWebRiskCalc261/support_definitions.html.
Statistical Analysis
Seventy percent of the data (n ¼ 13,617) was randomly selected to de-
velop the risk score model with the remaining 30% (n¼ 5926) reserved for
model validation. Baseline characteristics and clinical event rates were de-
scribed using medians with 25th and 75th percentiles for continuous vari-
ables and frequencies and proportions for categorical variables. Descriptive
data were compared using the Wilcoxon rank–sum test for continuous andThe Journal of Thoracic and Cordinal variables and a Pearson c2 or Fisher’s exact test for categorical vari-
ables. Multivariable logistic regression was performed to establish 2 differ-
ent scoring systems. The first logistic regression was performed to assess
the association between preoperative characteristics and the risk of opera-
tive mortality. A second logistic regression was performed to assess the as-
sociation between preoperative characteristics and a composite end point of
death and major complication. The study composite end point was defined
as any of the following postoperative events occurring before discharge or
within 30 days of surgery: death, deep sternal wound infection, postopera-
tive stroke, prolonged ventilation, pneumonia, renal failure, dialysis, mul-
tisystem organ failure, and readmission within 30 days.
Covariates were selected on the basis of univariable analysis and previ-
ous STS model variables. Data were fit in the logistic regression using
a generalized equation estimation to account for within-site correlation.
A parsimonious subset of 14 variables was selected that explained more
than 93% of the variation in the full model. To create a simplified risk scor-
ing system, wemultiplied regression coefficients from the simplifiedmodel
by a factor of 15 and then rounded them to the nearest integer. Because the
data used in analyses of the STS ACSD represent a limited data set (no di-
rect patient identifiers) that was originally collected for nonresearch pur-
poses, and the investigators do not know the identity of individual
patients, the analysis of these data was declared by the Duke University
Health System Institutional Review Board to be research not involving hu-
man subjects and is therefore considered exempt.11 All statistical analyses
were performed using SAS version 8.2 software (SAS Institute, Cary, NC).
RESULTS
Patient demographics are listed in Table 1. The median
age of patients undergoing surgery for IE was 55 years
(45–66 years) and the majority of patients were male
(66.7%). Reflecting the severity of illness of patients with
IE, 23.3% of the patients were in renal failure with
13.3% receiving renal dialysis. Over half (51.5%) of the
patients undergoing surgery for IE were classified as having
active endocarditis at the time of surgery. Again, active
endocarditis is defined by the STS as any patient currently
receiving antibiotic therapy at the time of surgery. Patients
receiving routine prophylactic antibiotics for surgery were
not included. Preoperative stroke (defined as a neurologic
deficit lasting more than 24 hours) was present in 18.9%
(n ¼ 2580) of patients in the study. In this group of patients
with preoperative stroke, 29.4% (n ¼ 759) were classified
as having recent stroke (within 2 weeks of surgery) and
67.1% (n ¼ 1732) were classified as having had remote
strokes (>2 weeks before surgery). Previous cardiac surgery
was present in the study as prior coronary artery bypass
grafting (7.9%), prior valve surgery (20.5%), or other prior
cardiac surgery (3.9%). The total percentage of patients un-
dergoing redo surgery for IE was 32.9% (n¼ 4480). Valvu-
lar dysfunction included mitral insufficiency (54.17%),
aortic insufficiency (40.65%), and tricuspid insufficiency
(16.30%).
The operative statistics and complications are listed in
Table 2. Of the total 13,617 surgical procedures analyzed
for the risk model, the majority were classified as urgent
(49.8%). The operations were documented as elective in
42.95% of patients with 6.79% classified as emergency
and 0.49% classified as salvage. In the overall population,ardiovascular Surgery c Volume 141, Number 1 99
TABLE 1. Distribution of baseline characteristics
Variable Level N
Overall
(%)
Age (y) Median 13617 55.00
25th 45.00
75th 66.00
Mean 55.11
Gender (%) Male 9092 66.77
Female 4525 33.23
Race (%) White and others 10593 77.79
African American 2113 15.52
Hispanic 624 4.58
Asian 235 1.73
Mixed 52 0.38
Surgery year (%) 2002 1247 9.16
2003 1765 12.96
2004 1799 13.21
2005 2068 15.19
2006 2412 17.71
2007 2404 17.65
2008 1922 14.11
Body surface area (%) <1.5 494 3.63
1.5 and<1.75 2709 19.89
1.75 and<2 5190 38.11
2 5126 37.64
Prior tobacco use (%) 7027 51.60
Diabetes (%) Insulin-dependent 1504 11.05
Non–insulin-dependent 1697 12.46
Hypercholesterolemia (%) 4867 35.74
Renal failure (%) 3174 23.31
Preoperative dialysis (%) 1807 13.27
Hypertension (%) 7658 56.24
Active endocarditis (%) 7022 51.57
Chronic lung
disease/COPD (%)
3109 22.83
Immunosuppressive
treatment (%)
933 6.85
Peripheral vascular
disease (%)
1494 10.97
Cerebrovascular
disease (%)
No prior stroke 596 4.38
Prior stroke 2580 18.95
Arrhythmia (%) 2638 19.37
Reoperation (%) 0 previous 10320 75.79
1 previous 2623 19.26
2þprevious 674 4.95
Prior CABG (%) 1079 7.92
Prior valve surgery (%) 2803 20.58
Prior other cardiac surgery (%) 535 3.93
Preoperative steroids (%) 962 7.06
No. of diseased
coronary vessels (%)
None 11313 83.08
One 1137 8.35
Two 618 4.54
Three 373 2.74
Four or greater 176 1.29
Left main disease (%) 323 2.37
(Continued)
TABLE 1. Continued
Variable Level N
Overall
(%)
Aortic stenosis (%) 1982 14.56
Mitral stenosis (%) 831 6.10
Tricuspid stenosis (%) 88 0.65
Pulmonic stenosis (%) 30 0.22
Aortic insufficiency
(moderate to severe) (%)
5535 40.65
Mitral insufficiency
(moderate to severe) (%)
7377 54.17
Tricuspid insufficiency
(moderate to severe) (%)
2220 16.30
Pulmonic insufficiency
(moderate to severe) (%)
344 2.53
COPD, Chronic obstructive pulmonary disease; CABG, coronary artery bypass
grafting.
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Dbioprosthetic valve replacement was the most commonly
performed operation, comprising 60.6% of total aortic
valve procedures and 42.17% of total mitral valve proce-
dures. Mechanical valves were used in 31.8% of aortic
valve operations, 27.16% of mitral valve operations, and
4.1% of tricuspid operations. The mitral valve had the high-
est rate of repair (24.6%), followed by the tricuspid valve
(11.78%) and aortic valve (0.22%). Overall, valve repair
was a minority of the procedures performed. The Ross pro-
cedure was rare, with only 5 reported cases in the database.
Operative mortality was 8.2%. Operative mortality by
valve type was 6.02% for isolated aortic valve procedures,
7.89% for isolated mitral valve procedures, and 6.07% for
isolated tricuspid valve procedures. Multiple valve surgery
carried the highest risk of operative mortality at 13.2%.
Postoperative complications were reported in 53% of pa-
tients. Median postoperative length of stay was 8 days. In
patients who had a major postoperative complication, the
mean postoperative length of stay was significantly longer
than in those without a major complication (18 days vs 9
days) (P<.0001). Reoperation for any reason was required
in 15% of patients. Within this subgroup, 6.2% required
reoperation for bleeding with a very small number requiring
reoperation for valvular dysfunction (0.5%). The rate of
deep sternal wound infection was low (0.5%). Prolonged
ventilation (>24 hours) (27.9%) was the most commonly
reported complication, followed by atrial fibrillation
(19.5%). Despite a relatively high rate of preoperative cere-
brovascular disease (23.3%; n¼ 3176), of which the major-
ity (81%; n ¼ 2580) were strokes, the rate of new
postoperative neurologic complications was low. Any neu-
rologic complication occurred in 4.4% of patients, of which
2.6% were classified as stroke. Transient neurologic deficit
was documented in 0.95%, and continuous coma was pres-
ent in 1.18%. When examining stroke rate in patients with
a documented preoperative stroke (n¼ 2580), we found thatery c January 2011
TABLE 2. Operative statistics and outcomes
Variable Level N ¼ 13,617
Overall
(%)
Status of the procedure (%) Elective 5848 42.95
Urgent 6778 49.78
Emergency 924 6.79
Emergency salvage 67 0.49
Coronary artery bypass
grafting (%)
2304 16.92
Aortic valve procedure (%) Total 4866 35.73
Mechanical valve 1546 31.77
Biologic valve 2952 60.66
Homograft 256 5.26
Missing 96 1.97
Ross procedure 5 0.10
Repair 11 0.22
Mitral valve procedure (%) Total 5478 40.23
Mechanical valve 1488 27.16
Biologic valve 2310 42.16
Homograft 8 0.15
Missing 318 5.80
Autograft 6 0.11
Repair 1348 24.60
Tricuspid valve procedure (%) Total 560 4.11
Mechanical valve 23 4.10
Biologic valve 307 54.82
Homograft 1 0.17
Missing 160 28.57
Autograft 3 0.53
Repair 66 11.78
Multiple valve
procedure (%)
2713 19.92
Any postoperative
complication (%)
7236 53.14
Reoperation for any
reason (%)
2042 15.00
Reoperation for
bleeding (%)
838 6.15
Reoperation for valvular
dysfunction (%)
67 0.49
Reoperation for graft
occlusion (%)
6 0.04
Reoperation for other
cardiac problem (%)
463 3.40
Reoperation for other
noncardiac problem (%)
949 6.97
Perioperative myocardial
infarction (%)
168 1.23
Any infection (%) 759 5.57
Mediastinitis (%) 67 0.49
Sepsis (%) 586 4.30
Any neurologic complication (%) 599 4.40
Postoperative stroke>72 h (%) 357 2.62
Transient neurologic deficit (%) 130 0.95
Continuous coma>24 h (%) 161 1.18
Any pulmonary complication (%) 3592 26.38
(Continued)
TABLE 2. Continued
Variable Level N ¼ 13,617
Overall
(%)
Prolonged ventilation (%) 3809 27.97
Pulmonary embolism (%) 36 0.26
Pneumonia (%) 771 5.66
Renal failure (%) 803 5.90
Postoperative dialysis (%) 548 4.02
Any vascular complication (%) 128 0.94
Acute limb ischemia (%) 117 0.86
Heart block (%) 846 6.21
Anticoagulant
complication (%)
432 3.17
Cardiac arrest (%) 518 3.80
Tamponade (%) 155 1.14
Gastrointestinal
complication (%)
742 5.45
Multisystem organ failure (%) 440 3.23
Atrial fibrillation (%) 2644 19.42
Other complication (%) 1199 8.81
Total length of stay (d) Median 13575 14.00
25th 8.00
75th 24.00
Mean 18.90
Postoperative length
of stay (d)
Median 13576 8.00
25th 6.00
75th 14.00
Mean 12.64
Preoperative length of stay (d)
Recent stroke (<2 wk) Median 759 7.00
Remote stroke (>2 wk) Median 1729 5.00
Postoperative length
of stay (d)
Recent stroke (<2 wk) Median 755 11.00
Remote stroke (>2 wk) Median 1725 9.00
In-hospital mortality (%) 1046 7.68
Operative mortality
Overall (%) 1117 8.20
Isolated aortic valve
procedures (n ¼ 4866)
293 6.02
Isolated mitral valve
procedures (n ¼ 5478)
432 7.89
Isolated tricuspid valve
procedures (n ¼ 560)
34 6.07
Multiple valve procedures
(n ¼ 2713)
358 13.20
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Dthe rate of postoperative stroke was similarly low at 4.34%
(n ¼ 112). In those patients with preoperative stroke, the
median preoperative length of stay was 7 days compared
with 5 days in those without preoperative stroke. The post-
operative length of stay was longer (11 days) in patients
with a recent stroke (within 2 weeks of operation) than in
those with a remote stroke (9 days).
The results of the simplified model predicting the com-
posite end point of major morbidity or mortality are listedrdiovascular Surgery c Volume 141, Number 1 101
FIGURE 1. A, Observed versus expected mortality after surgery for endo-
carditis based on bedside risk score. B, Observed versus expected major
morbidity and mortality after surgery for endocarditis based on beside
risk score.
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plained more than 93% of the variation in the full logistic
regression (Table E1). According to their predictive value,
each variable was assigned a corresponding point score,
also listed in Table 3. The most important predictor of the
composite end point of death or major complication was
an operation classified as emergency, emergency/salvage,
or cardiogenic shock. The second most important predictive
value was renal failure or a preoperative creatinine level
greater than 2.0 mg/dL. The points assigned to the remain-
ing variables are also listed in Table 3. The relationship
between the observed composite end point of major mor-
bidity or mortality and that predicted by this model in the
test group of patients is illustrated graphically in Figure 1,
A. The model demonstrated good predictive ability com-
pared with observed mortality with a C statistic of 0.72870.
Logistic regression analysis also was performed for the
predictors of the sole end point of operative mortality
(Table E2). The results of this simplified model are demon-
strated in Table 4. As with the composite end point, the
model consisted of the 13 most important variables that ex-
plained more than 93% of the variation in the full logistic
regression model (Table E2). An operation classified as
emergency, emergency/salvage, or cardiogenic shock was
the most powerful predictor of operative mortality, with
the secondmost important predictor renal failure or a preop-
erative creatinine level greater than 2.0 mg/dL. The next
most important predictors of mortality were active (vs
treated) endocarditis and the use of preoperative inotropic
therapy and/or an intra-aortic balloon pump. Several vari-
ables were predictive in the composite end point model
but did not reach significance in the predictivemodel for op-
erative mortality alone. Age greater than 60 years, body sur-
face area greater than 1.9, female gender, and New York
Heart Association class IV heart failure were all predictors
in the composite model but did not prove significant as theTABLE 3. Simplified model and point estimate for the composite end poin
Parameter Standard estimate
Female gender 0.30923
BSA>1.9 0.09389
Age>60 0.26839
Prior CABG 0.32403
Status: urgent or emergency, no cardiogenic shock 0.40854
Status: emergency, salvage, or cardiogenic shock 1.13463
Preoperative IABP or inotropes 0.83191
Multiple valve procedure 0.45954
Prior valve surgery 0.32296
IDDM 0.48610
NYHA class IV 0.38932
Active endocarditis 0.45781
Renal failure or Cr>2.0 0.77041
Arrhythmia 0.31833
C statistic ¼ 0.72870. OR, Odds ratio; CI, confidence interval; BSA, body surface area; C
insulin-dependent diabetes mellitus; NYHA, New York Heart Association; Cr, creatinine.
102 The Journal of Thoracic and Cardiovascular Surgpredictor of operative mortality alone. These variables were
replaced in the mortality-alone model by chronic lung dis-
ease, non–insulin-dependent diabetes, and hypertension.
However, the most powerful predictors of both operativet of major morbidity and mortality
Probability OR CI Points
< .0001 1.36237 (1.35, 1.38) 5
< .0001 1.09844 (1.09, 1.11) 1
< .0001 1.30786 (1.30, 1.32) 4
< .0001 1.38269 (1.37, 1.40) 5
< .0001 1.50461 (1.49, 1.52) 6
< .0001 3.11004 (3.04, 3.18) 17
< .0001 2.29770 (2.26, 2.34) 12
< .0001 1.58334 (1.57, 1.60) 7
< .0001 1.38121 (1.37, 1.40) 5
< .0001 1.62597 (1.60, 1.65) 7
< .0001 1.47598 (1.46, 1.49) 6
< .0001 1.58061 (1.57, 1.60) 7
< .0001 2.16064 (2.14, 2.18) 12
< .0001 1.37484 (1.36, 1.39) 5
ABG, coronary artery bypass grafting; IABP, intra-aortic balloon pumping; IDDM,
ery c January 2011
TABLE 4. Simplified model and point estimate for postoperative mortality
Parameter Standard estimate Probability OR CI Points
Prior CABG 0.48958 <.0001 1.63163 (1.60, 1.67) 7
Status: urgent or emergency, no cardiogenic shock 0.42207 <.0001 1.52511 (1.50, 1.55) 6
Status: emergency, salvage, or cardiogenic shock 1.15279 <.0001 3.167 (3.03, 3.31) 17
Preoperative IABP or Inotropes 0.67227 <.0001 1.95869 (1.89, 2.03) 10
Multiple valve procedure 0.602 <.0001 1.82577 (1.79, 1.86) 9
Prior valve surgery 0.47119 <.0001 1.6019 (1.57, 1.64) 7
IDDM 0.54652 <.0001 1.72723 (1.68, 1.78) 8
NIDDM 0.43098 <.0001 1.53877 (1.50, 1.58) 6
Hypertension 0.342 <.0001 1.40776 (1.38, 1.43) 5
Chronic lung disease 0.34443 <.0001 1.41119 (1.38, 1.44) 5
Active endocarditis 0.69541 <.0001 2.00453 (1.97, 2.04) 10
Renal failure or Cr>2.0 0.82723 <.0001 2.28698 (2.24, 2.33) 12
Arrhythmia 0.5043 <.0001 1.65582 (1.62, 1.69) 8
C statistic¼ 0.75784. OR, Odds ratio; CI, confidence interval; CABG, coronary artery bypass grafting; IABP, intra-aortic balloon pump; IDDM, insulin-dependent diabetes mel-
litus; NIDDM, non–insulin-dependent diabetes mellitus; Cr, creatinine.
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remained similar. This model also demonstrated good pre-
dictive ability compared with observed mortality with a C
statistic of 0.75784. In both models, ‘‘any valve repaired’’
(compared with replacement) was associated with im-
proved survival and decreased morbidity (Tables E1 and
E2). This effect was largely due to repair of the mitral
valve (9.91%) inasmuch as the rates of repair for
tricuspid (0.48%) and aortic valves (0.08%) were low.
DISCUSSION
The patient with IE often presents a challenging clinical
dilemma. In the critically ill patient, surgical therapy for IE
can be lifesaving. Despite the evidence that the incidence of
IE is increasing with time, however, few data are available
to guide surgical decision-making. The purpose of this
study was to develop a simplified risk score model that
could aid in clinical decisions in the patient with IE. Ac-
cording to this information, a patient with a preoperative
score of 35 points on both models would be expected to
have an operative risk of at least 10% mortality and 60%
combined major morbidity and mortality. The overall mor-
tality in this series was 8.2%. This mortality is significantly
lower than the reported mortality for dialysis patients under-
going surgery for IE (24.4%) and the reported in-hospital
mortality for all patients with IE (>20%).2,3,6 Although
the morbidity in this series was high relative to other
categories, surgical therapy remains very effective in the
treatment of patients with IE.
The preoperative hemodynamic condition of the patient
was the greatest predictor of mortality and major morbidity
after surgery for IE. Those patients in the emergency, sal-
vage, or cardiogenic shock classes clearly had worse out-
comes after surgery than those who were not in these
classes. This finding is consistent with other risk models
of cardiac surgery, specifically those in coronary artery
bypass grafting as well as valvular heart disease.12 The im-The Journal of Thoracic and Caportance of this model, however, is that it can assign a rela-
tive weight to the other preoperative variables through the
development of the scoring system, as shown in Tables 3
and 4. Using this point scoring system, a clinician can
develop a preoperative bedside risk profile that can
greatly facilitate the decision-making process in often diffi-
cult clinical scenarios. Even among patients with the high-
est point scores, the actual and predicted operativemortality
did not exceed 30%, suggesting that future patient selection
should be fairly liberal, although exact selection criteria
used in the included patients cannot be documented.
In the model, preoperative cerebrovascular disease was
not a significant predictor of operative morbidity or mortal-
ity. In addition, the rate of postoperative cerebrovascular
complications was low at 4.4%, of which 2.6% were clas-
sified as stroke. Preoperative cerebrovascular disease has
been identified as a risk factor for in-hospital mortality
from cardiac valve surgery.12,13 However, it was not
identified as a risk factor for in-hospital mortality in patients
with dialysis-dependent renal failure who underwent sur-
gery for IE.6 Similarly, the results of this analysis suggest
that preoperative cerebrovascular disease is not a risk factor
for postoperative complications in patients with IE. Even
among patients with a recent preoperative stroke, the rate
of postoperative stroke was low (4.3%) with a median of
only 7 days between hospital admission and operation.
These data suggest that the recommended practice of delay-
ing surgery after a recent stroke from IE before proceeding
with cardiac surgery may need re-examination.14
One finding of concern in this study was that risk-
adjusted surgical mortality has remained relatively stable
over the period of the study. IE, however, is a constantly
changing disease. The rapid increase in staphylococcal
infections and an increase in cardiac device implantations
make it difficult to compare surgical results from year to
year.15 The finding that those patients classified as having
‘‘active’’ endocarditis contributed significantly to therdiovascular Surgery c Volume 141, Number 1 103
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Dsurgical risk identifies this as one area for possible improve-
ment. However, converting patients from ‘‘active’’ to
‘‘treated’’ status must be counterbalanced against the risk
of postponing surgery to complete antibiotic therapy.
Indeed, postponing surgery may increase the risks of inter-
vening complications of IE, such as embolization, heart
failure, and death.
Converting the patient to treated status could also facili-
tate another candidate for possible quality improvement:
valve repair. This has been identified as an area of improve-
ment in other series of surgical IE patients, particularly
related to the mitral valve.16,17 Indeed, in this study ‘‘any
valve repair’’ also was predictive of better outcomes in
this study. More patients converted to treated status may
facilitate higher rates of valve repair.17 This approach how-
ever, must be individualized to the clinical scenario. In
some cases, early surgery of active IE may allow more
patients to undergo repair, inasmuch as further valvular de-
struction is avoided. Although the short-term results of
valve repair in IE are promising, the long-term outcomes
in IE are not known at this time.17
Although patients with treated IE who underwent valve
repair had better outcomes in this study, a strong selection
bias probably exists in these results. That is, patients with
a more indolent form of IE were more likely to tolerate a pe-
riod of antibiotic therapy and subsequently be candidates
for valve repair. Nevertheless, 43% of all surgical proce-
dures performed in the study were classified as elective,
demonstrating that large numbers of patients could possibly
tolerate an antibiotic regimen and subsequent repair. The
rates of valve repair in this study, however, remain relatively
low. Mitral valve repair represented only 24.6% of all
mitral valve procedures performed. The rate of mitral valve
repair in this database analysis is lower than published
reports from single centers, suggesting that increasing the
rate of mitral valve repair is indeed possible and may im-
prove outcomes.3,17,18 Indeed, with the development of
new valve repair techniques, such as the use of autologous
pericardium and artificial chordal replacement, it may be
possible to increase the rate of valve repair to include the
tricuspid and aortic valves.19-21
The limitations of this study reflect the limitations of
a retrospectively collected database. The STS ACSD data
supplied for this analysis consisted of data submitted volun-
tarily from 824 participating centers in North America. In
addition, the STS ACSD does not provide outcomes beyond
the 30-day perioperative period, and long-term follow-up is
not available. However, operative mortality is a significant
variable in IE, and the study does represent the largest series
of the surgical treatment of IE to date in the literature. An
important undefined potential confounding variable in the
data set is etiologic organism. The current STS data submis-
sion form does not provide microbiologic information. The
type of microorganism involved in IEmay have a significant104 The Journal of Thoracic and Cardiovascular Surgeffect on surgical outcomes, but it is not captured in this
analysis. Management principles may change, depending
on the etiologic organism, especially with infections involv-
ing resistant staphylococci and fungi. One additional, and
key, limitation is that this series includes both native valve
endocarditis and prosthetic valve endocarditis, inasmuch
as the current STS data set does not distinguish between
the two. These deficiencies are being corrected in future
data sets. The inclusion of tricuspid valve endocarditis is
this analysis is another possible confounding variable. Al-
though patients with tricuspid valve disease make up a mi-
nority of the study population, right-sided and left-sided IE
may represent different disease entities. Future studies will
be aided by refinements to the database, allowing us to study
more homogeneous patient populations.
In summary, the surgical patient with IE remains a signif-
icant clinical challenge. Data from this analysis confirms
that surgery is a very effective tool in the management of
these complex patients. Even with relatively high risk
‘‘scores,’’ mortality rates are less than 10%. Surgical mor-
bidity and mortality depend on variety of preoperative fac-
tors, most important, the preoperative hemodynamic status
of the patient. The risk scoring system presented here in-
forms patient selection, provides risk stratification, and al-
lows communication with patients and other physicians.References
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Dr James M. Douglas (Bellingham, Wash). I congratulate the
authors on their monumental undertaking to develop a comprehen-
sible risk assessment system for the evaluation of the very diverse
and often exceedingly high-risk population of patients undergoing
surgical treatment of endocarditis. In this paper the authors have
convincingly demonstrated the importance of a number of preop-
erative risk factors in this patient cohort that I am certain wewould
all agree are legitimate. However, I am equally intrigued by the
number of questions that may be stimulated by examining this
large data set. To adhere to the time constraints, I will limit these
thoughts to just a few.
Ever sinceWill C. Sealy at Duke proved the improbable by suc-
cessfully performing valve replacement in the patient with active
endocarditis, surgeons have relied on a set of surgical indications
that include congestive heart failure, persistent infection, paravalv-
ular extension, valvular dysfunction, and recurrent emboli. In
essence, surgery has generally been performed in patients in
whommedical therapy has failed. Unfortunately, many of the high-
est risk patients will also die with surgery. Although the scoring
system will confirm what we already know, that is, that the patient
is at high risk, my first question is, can you tell us which patient will
likely die? More specifically, were you able to identify any patient
subgroup for which surgical intervention would be unwise?
My second question is along a similar line. The most important
risk factors for morbidity and mortality that you identified were
primarily functional or physiologic. Using these criteria, you
stated in the paper that the subgroup of patients with the highest
risk scores had operative mortalities that did not exceed 30%.
However, the most vexing patients with endocarditis are those
with serious anatomic challenges, including pseudoaneurysms,
fistulas, and extensive paravalvular abscesses, especially in theThe Journal of Thoracic and Casetting of prosthetic valve endocarditis. Do you believe that the
physiologic parameters trump these anatomic considerations or
would inclusion of these factors in a database better help us to
stratify these patients?
Last, one of your coauthors, Dr Gammie, has previously mined
a database and provided strong support for the use of mitral valve
repair in the treatment of endocarditis. This study likewise attests
to the potential superiority of this approach when feasible. Despite
these data, surgeons may still question the superiority of the tech-
nique itself versus patient selection bias in this heterogeneous pop-
ulation. What are your thoughts on this topic and how do you
suggest we resolve with persistent issue?
Dr Gaca. Who will die? I think that is very interesting. Even
with the highest risk score, our mortality rates, as you correctly
pointed out, did not exceed 30%, so that means every one in this
room is already making these decisions on who will die and who
will not die. That is really a limitation of the database. Only the
people who get surgery are in the database, and I think that we
are doing a very good job. I think we can do better, but that is
the eternal question. That goes into your other question, the lim-
itations of the database. Yes, there are anatomic factors and, no,
they are not included in the database. The big limitation to this
database is that we do not have microbiology data, and one of
the limitations is that we lumped prosthetic valve endocarditis
in with native valve endocarditis. I think that in future data
sets we are going to include the microbiology in the STS data-
base and we are going to try to look at prosthetic endocarditis
alone, because that as you probably can imagine is a different an-
imal. This speaks to the importance of doing these database pa-
pers, because they examine our own clinical practice and allow
us to refine further data sets to answer the questions that you
have raised.
As for mitral repair, you are right. One of our authors has been
a steadfast proponent of mitral valve repair, and indeed mitral
valve repair in this study has actually shown an improved survival.
Obviously not everyone can undergo repair, and are they having
valve repair because their disease is more indolent? That is possi-
ble. Do you we have long-term data? No. I think the next study we
need to do is to link this kind of data to Centers for Medicare and
Medicaid Services data to see what the long-term survival is of
these patients. That is really the next step beyond these STS data
base papers.
DrAnthony Furnary (Portland, Ore). Jeff, you said—I am just
going to read from your abstract—‘‘Interestingly, risk-adjusted
mortality is not improved in recent years, with operative mortality
for 2008 having increased relative to previous years.’’ Did you
present that information?
DrGaca.That is in the paper.We did not present it, but it is true.
Operative mortality from this disease is not getting better, and I
think that has a lot to dowith the fact that endocarditis is a changing
disease. There are a lot more devices being put in people. There is
a rise in staphylococcal infections, so the endocarditis of 5 to 10
years ago is not the same endocarditis that we see this year.
Dr Furnary. Is the risk-adjusted mortality, O/E ratio, getting
worse?
Dr Gaca. It is not improving.
Dr Furnary. It is not getting better.
Dr Gaca. Yes, it is stagnant.rdiovascular Surgery c Volume 141, Number 1 105
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rithms for all valve disease. Would there be a better agreement
or area under the raw curve if you segregated out mitral versus aor-
tic versus tricuspid?
Dr Gaca. Yes, I think so, mainly because people were able to
repair more of the mitral valves. I think the curves for the aortic
and tricuspid valves will be diferent.
Dr Furnary. That is something you would consider?
Dr Gaca. Yes.
Dr Jack Copeland (Tucson, Ariz). Many databases in the past
years have shown a history of smoking as a very powerful predictor
of bad outcome. We have seen it in transplantation and in bridge to
transplantation. Yesterday it was presented as a predictor of bad106 The Journal of Thoracic and Cardiovascular Surgoutcome in lung surgery. Did you include this as part of your anal-
ysis and was it predictive of bad outcome?
Dr Gaca. That is a good question. Smoking was included. It is
in the full model and it was not predictive, but, yes, it is in the
model.
Speaker. Jeff, when you publish your paper in the Journal,
would you be so kind as to publish both the beta coefficients and
the intercept so that we can use these clinically in our centers,
and would you consider publishing separate information for mi-
tral, aortic, and tricuspid?
Dr Gaca. Yes, that information is available. It will be in the
on-line tables owing to the constraints of the Journal, but we
will publish that information.ery c January 2011
TABLE E1. Full logistic regression model and point estimate for composite end point of major morbidity and mortality
Parameter Estimate P value Odds ratio 95% CI
Year of surgery
2008 0.2267 .1439 0.797 (0.59, 1.08)
2007 0.4140 .0034 0.661 (0.5, 0.87)
2006 0.3723 .0079 0.689 (0.52, 0.91)
2005 0.3388 .0214 0.713 (0.53, 0.95)
2004 0.1622 .2371 0.85 (0.65, 1.11)
2003 0.0745 .6212 0.928 (0.69, 1.25)
2002 (reference) 0.0000 1 (1, 1)
Female gender 0.4776 <.0001 1.612 (1.38, 1.89)
Body surface area 0.2144 .2070 1.239 (0.89, 1.73)
Age 0.0275 <.0001 1.028 (1.02, 1.03)
Dialysis 1.2246 <.0001 3.403 (2.55, 4.54)
Renal failure/creatinine>2 without dialysis 0.6545 <.0001 1.924 (1.59, 2.33)
Normal creatinine (reference) 0.0000 1 (1, 1)
Urgent or emergency status without shock 0.3700 <.0001 1.448 (1.22, 1.72)
Emergency, salvage, or cardiogenic shock 1.0594 <.0001 2.885 (2.18, 3.81)
Congestive heart failure 0.0225 .7646 1.023 (0.88, 1.19)
Active endocarditis 0.7332 <.0001 2.082 (1.76, 2.46)
Preoperative inotropes or IABP 0.5317 <.0001 1.702 (1.38, 2.1)
One distal coronary anastomosis 0.1799 .0846 1.197 (0.98, 1.47)
Two distal coronary anastomoses 0.3234 .0208 1.382 (1.05, 1.82)
Three distal coronary anastomoses 0.2683 .1319 1.308 (0.92, 1.85)
Four or more distal coronary anastomoses 0.6134 .0102 1.847 (1.16, 2.95)
Multiple valve surgery 0.8274 <.0001 2.287 (1.88, 2.78)
Tricuspid valve surgery 0.4257 .0218 1.531 (1.06, 2.2)
Mitral valve surgery 0.2420 .0027 1.274 (1.09, 1.49)
Aortic valve surgery (reference) 0.0000 1 (1, 1)
Prior CABG 0.2010 .0717 1.223 (0.98, 1.52)
Prior valve surgery 0.4156 <.0001 1.515 (1.28, 1.79)
IDDM 0.3728 .0002 1.452 (1.19, 1.77)
NIDDM 0.2984 .0008 1.348 (1.13, 1.6)
NYHA class IV 0.1773 .0351 1.194 (1.01, 1.41)
African American race 0.0723 .4488 1.075 (0.89, 1.3)
Preoperative steroid administration 0.1399 .2740 1.15 (0.9, 1.48)
Hypertension 0.1024 .1881 1.108 (0.95, 1.29)
Myocardial infarction within last 7 days 0.5033 .0003 1.654 (1.26, 2.17)
Immune suppressive treatment 0.1211 .3512 1.129 (0.87, 1.46)
Chronic lung disease 0.2207 .0019 1.247 (1.08, 1.43)
Peripheral vascular disease 0.1565 .0907 1.169 (0.98, 1.4)
Smoker 0.1204 .0801 1.128 (0.99, 1.29)
Arrhythmia 0.2640 .0009 1.302 (1.11, 1.52)
Any valve repaired 0.2786 .0023 0.757 (0.63, 0.91)
C index ¼ 0.80046. CI, Confidence interval; IABP, intra-aortic balloon pumping; CABG, coronary artery bypass grafting IDDM, insulin-dependent diabetes mellitus; NIDDM,
non–insulin-dependent diabetes mellitus; NYHA, New York Heart Association.
Gaca et al Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 141, Number 1 106.e1
A
C
D
TABLE E2. Full logistic regression model and point estimate for operative mortality
Parameter Estimate P value Odds Ratio 95% CI
Year of surgery
2008 0.2267 .1439 0.797 (0.59, 1.08)
2007 0.4140 .0034 0.661 (0.5, 0.87)
2006 0.3723 .0079 0.689 (0.52, 0.91)
2005 0.3388 .0214 0.713 (0.53, 0.95)
2004 0.1622 .2371 0.85 (0.65, 1.11)
2003 0.0745 .6212 0.928 (0.69, 1.25)
2002 (reference) 0.0000 1 (1, 1)
Female gender 0.4776 <.0001 1.612 (1.38, 1.89)
Body surface area 0.2144 .2070 1.239 (0.89, 1.73)
Age 0.0275 <.0001 1.028 (1.02, 1.03)
Dialysis 1.2246 <.0001 3.403 (2.55, 4.54)
Renal failure/creatinine>2 without dialysis 0.6545 <.0001 1.924 (1.59, 2.33)
Normal creatinine (reference) 0.0000 1 (1, 1)
Urgent or emergency status without shock 0.3700 <.0001 1.448 (1.22, 1.72)
Emergency, salvage, or cardiogenic shock 1.0594 <.0001 2.885 (2.18, 3.81)
Congestive heart failure 0.0225 .7646 1.023 (0.88, 1.19)
Active endocarditis 0.7332 <.0001 2.082 (1.76, 2.46)
Preoperative inotropes or IABP 0.5317 <.0001 1.702 (1.38, 2.1)
One distal coronary anastomosis 0.1799 .0846 1.197 (0.98, 1.47)
Two distal coronary anastomoses 0.3234 .0208 1.382 (1.05, 1.82)
Three distal coronary anastomoses 0.2683 .1319 1.308 (0.92, 1.85)
Four or more distal coronary anastomoses 0.6134 .0102 1.847 (1.16, 2.95)
Multiple valve surgery 0.8274 <.0001 2.287 (1.88, 2.78)
Tricuspid valve surgery 0.4257 .0218 1.531 (1.06, 2.2)
Mitral valve surgery 0.2420 .0027 1.274 (1.09, 1.49)
Aortic valve surgery (reference) 0.0000 1 (1, 1)
Prior CABG 0.2010 .0717 1.223 (0.98, 1.52)
Prior valve surgery 0.4156 <.0001 1.515 (1.28, 1.79)
IDDM 0.3728 .0002 1.452 (1.19, 1.77)
NIDDM 0.2984 .0008 1.348 (1.13, 1.6)
NYHA class IV 0.1773 .0351 1.194 (1.01, 1.41)
African American race 0.0723 .4488 1.075 (0.89, 1.3)
Preoperative steroid administration 0.1399 .2740 1.15 (0.9, 1.48)
Hypertension 0.1024 .1881 1.108 (0.95, 1.29)
Myocardial infarction within last 7 days 0.5033 .0003 1.654 (1.26, 2.17)
Immune suppressive treatment 0.1211 .3512 1.129 (0.87, 1.46)
Chronic lung disease 0.2207 .0019 1.247 (1.08, 1.43)
Peripheral vascular disease 0.1565 .0907 1.169 (0.98, 1.4)
Smoker 0.1204 .0801 1.128 (0.99, 1.29)
Arrhythmia 0.2640 .0009 1.302 (1.11, 1.52)
Any valve repaired 0.2786 .0023 0.757 (0.63, 0.91)
C index ¼ 0.78295. CI, Confidence interval; IABP, intra-aortic balloon pump; IDDM, insulin-dependent diabetes mellitus; NIDDM, non–insulin-dependent diabetes mellitus.
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